Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2005, Pages 91-96

  Qasim, Asghar ^a   Sebastian, Shaji ^a   Thornton, Orla ^a   Dobson, Mark ^a   McLoughlin, Ramona ^a   Buckley, Martin ^a   O'Connor, Humphrey ^a   O'Morain, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; BISMUTH SALT; CARBON 13; CLARITHROMYCIN; EPHEDRINE; FURAZOLIDONE; ISOCARBOXAZID; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENELZINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PROTON PUMP INHIBITOR; RIFABUTIN; TRANYLCYPROMINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BONE MARROW SUPPRESSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PEPTIC ULCER; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STANDARD; TREATMENT FAILURE; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; DRUG EVALUATION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; TREATMENT FAILURE;

EID: 12944305806     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02210.x     Document Type: Article

References (37)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concept in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
2. The European Helicobacter pylori Study Group. Current European concept in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-14.
3. American Gastroenterological Association. American Gastroenterological Association medical position statement. Evaluation of dyspepsia. Gastroenterology 1998; 114: 549-58.
4. Hunt R, Thompson ABR. Canadian Helicobacter consensus conference. Can J Gastroenterol 1998; 12: 31-41.
5. Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 667-73.
6. Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002; 97: 857-60.
7. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
8. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omerazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomised, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7.
9. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
10. Dixon F, Genta RM, Yardley JH, Corea P and the Participants in the International Workshop on the Histolpathology of Gastritis, Houston 1994. Classification and grading of gastritis. Am J Surg Pathol 1996; 20: 1161-80.
11. Veldhuyzen van Zanten SJO, Bradette M, Parley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
12. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
13. Damman HG, Folsch UR, Hahn EG, et al. Eradication of H. pylori with pantoprazole, clarithromycin, and metrinidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter 2000; 5: 41-51.
14. Qasim A, O'Morain CA. Review article: Treatment of Helicobacter pylori infection and factor influencing eradication. Aliment Pharmacol Ther 2002; 16 (Suppl. 1): 24-30.
15. Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-16.
16. Lee JM, Deasy E, O'Morain CA. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol 2000; 12: 433-7.
17. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci 2000; 45: 265-71.
18. Labenz J, Malfertheiner P. Helicobacter pylori - when and how do gastroenterologists treat themselves? A clinical and practical survey. Dtsch Med Wochenschr 1997; 133: 637-42.
19. Corea P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
20. Romano M, Marmo R, Cuobo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-8.
21. Chiba N, van Zanten SJO, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 1012.
22. Qasim A, Sebastian S, Buckley M, O'Connor H, O'Morain C. Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2004; 2: 85, discussion 85.
23. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
24. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553-60.
25. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-4.
26. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
27. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995; 21: 594-8.
28. Borody T, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol 2002; 97: 3032-7.
29. Russo F, Berloco P, Cuomo R, et al. Study from southern Italy. Helicobacter pylori strains and histologically related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther 2003; 17: 421-8.
30. Howden A, Boswell P, Tovey F. In-vitro sensitivity of Campylobacter pyloridis to furazolidone. Lancet 1986; 2: 1035.
31. Segura AM, Gutierrez O, Otero W, Angel A, Genta RM. Furazolidone, amoxicillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Phamracol Ther 1997; 11: 529-32.
32. Coelho LG, Martins GM, Passos MC, et al. Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. Aliment Pharmacol Ther 2003; 17: 131-6.
33. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-82.
34. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 225-31.
35. Graham DY, Ssato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HMT. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211-15.
36. Malekzadeh R, Ansari R, Vahedi H, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303.
37. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002; 16: 793-8.